Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Next Previous
Trial Profile

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Erythema; Flushing
  • Focus Therapeutic Use

Most Recent Events

  • 04 Dec 2019 Primary endpoint (Patient Erythema Self Assessment) has been met, according to the results published in the JAMA Dermatology.
  • 04 Dec 2019 Primary endpoint (Clinician Erythema Score) has been met, according to the results published in the JAMA Dermatology.
  • 04 Dec 2019 Results (n=20) published in the JAMA Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top